



Atty. Dkt. No. 059440-0128

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

#9/attach..

Applicant: Brian S. Hooker,

Title: METHOD OF PRODUCING
HUMAN COAGULATION FACTOR
VIII FROM WHOLE PLANTS OR
PLANT CELL CUTLURES

Appl. No.: 09/588,314

Filing Date: 06/06/2000

Examiner: M. Schmidt

Art Unit: 1635

RECEIVED
APR 05 2002
TECH CENTER 1600/2900

AMENDMENT TRANSMITTAL

Commissioner for Patents
Washington, D.C. 20231

Sir:

Transmitted herewith is an amendment in the above-identified application.

☒ Small Entity status under 37 C.F.R. § 1.9 and § 1.27 has been established by a Small Entity statement previously submitted.

☐ Small Entity statement is enclosed.

☒ The fee required for additional claims is calculated below:

	Claims as Amended	Previously Paid For	Extra Claims Present	Rate	Additional Claims Fee
Total Claims:	20	23	0	x \$18.00	\$0.00
Independents:	3	3	0	x \$84.00	\$0.00
First presentation of any Multiple Dependent Claims:				+ \$280.00	\$0.00
CLAIMS FEE TOTAL:					\$0.00

☒ Applicant hereby petitions for an extension of time under 37 C.F.R. §1.136(a) for the total number of months checked below:

<input type="checkbox"/>	Extension for response filed within the first month:	\$110.00	\$0.00
<input type="checkbox"/>	Extension for response filed within the second month:	\$400.00	\$0.00
<input checked="" type="checkbox"/>	Extension for response filed within the third month:	\$920.00	\$920.00
<input type="checkbox"/>	Extension for response filed within the fourth month:	\$1,440.00	\$0.00
<input type="checkbox"/>	Extension for response filed within the fifth month:	\$1,960.00	\$0.00
EXTENSION FEE TOTAL:			\$920.00
CLAIMS AND EXTENSION FEE TOTAL:			\$920.00
<input checked="" type="checkbox"/>	Small Entity Fees Apply (subtract ½ of above):		\$460.00
TOTAL FEE:			\$460.00

- ☐ Please charge Deposit Account No. 19-0741 in the amount of \$460.00. A duplicate copy of this transmittal is enclosed.
- ☒ A check in the amount of \$460.00 is enclosed.
- ☒ The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 C.F.R. §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 19-0741. Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 19-0741.

Please direct all correspondence to the undersigned attorney or agent at the address indicated below.

Respectfully submitted,

Date April 2, 2002

FOLEY & LARDNER
Washington Harbour
3000 K Street, N.W., Suite 500
Washington, D.C. 20007-5143
Telephone: (202) 672-5483
Facsimile: (202) 672-5399

By Richard C. Peet

Richard C. Peet
Attorney for Applicant
Registration No. 35,792



Atty. Dkt. No. 059440-128

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

#9 / R.T. 4/5

Applicant: Brian S. Hooker *et al.*

Title: METHOD OF PRODUCING HUMAN COAGULATION FACTOR FROM WHOLE PLANTS OR PLANT CELL CULTURES

RECEIVED

APR 05 2002

TECH CENTER 1600/2900

Appl. No.: 09/588,314

Filing Date: 06/06/2000

Examiner: M. Schmidt

Art Unit: 1635

AMENDMENT AND REPLY UNDER 37 C.F.R. §1.111

Commissioner for Patents
Washington, D.C. 20231

Sir:

In response to the Office Action mailed October 2, 2001, please amend the above-identified application as indicated below. Enclosed herewith is a Petition for a three-month extension of time to extend the time to respond to April 2, 2002. Should such a request or fee be deficient or absent, please consider this paragraph such a request and authorization to charge the appropriate fee under 37 C.F.R. §1.16 to 1.18 to Account No. 19-0741.

In the Claims:

In accordance with 37 CFR §1.121, please substitute for original claims 1,6-8, 13, 15-17, 19, 20, and 23, the following rewritten versions of the same claims, as amended. The changes are shown explicitly in the attached "Version with Markings to Show Changes Made."

Please cancel claims 11, 16 and 17, without prejudice or disclaimer.

1. (Amended) A method of producing a bioactive human coagulation factor VIII, comprising:

full-length